Proteomedix agrees to issue labcorp exclusive license for proclarix® blood test to detect prostate cancer

Zurich-schlieren, switzerland--(business wire)--proteomedix, a swiss diagnostics company committed to advancing prostate cancer care, announced today that it entered into an agreement for labcorp, a leading global life sciences company, to be the only laboratory to develop and commercialize the proclarix® prostate specific antigen (psa) test in the u.s.. proclarix is performed using the same blood sample as a psa test, and is designed to help determine the risk of clinically significant prostat.
LH Ratings Summary
LH Quant Ranking